What are you looking for?
A review of adverse events found relatively low complication rates associated with the Hydrus Microstent, iStent inject W, and iStent infinite glaucoma devices, according to a poster presented at the ARVO 2026 Annual Meeting. Researchers identified 426 reports containing 511 adverse events across the 3 devices. The most reported complications were stent malposition (32.9%), inflammation... ...
Switching to aflibercept 8 mg may allow longer treatment intervals while maintaining anatomical outcomes in patients with neovascular age-related macular degeneration (nARMD)...
Alain Bauza, MD, of Freehold Ophthalmology, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a study that assessed the...
Taylor Linaburg, MD, of OCLI Vision, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a study that found that...
A review of adverse events found relatively low complication rates associated with the Hydrus Microstent, iStent inject W, and iStent infinite glaucoma devices, according to a poster presented at the...
Switching to aflibercept 8 mg may allow longer treatment intervals while maintaining anatomical outcomes in patients with neovascular age-related macular degeneration (nARMD) who previously had a suboptimal response to anti-VEGF...
Alain Bauza, MD, of Freehold Ophthalmology, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a study that assessed the use of cryopreserved amniotic membrane in patients with...
Taylor Linaburg, MD, of OCLI Vision, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a study that found that use of cryopreserved amniotic membranes for ocular surface...
Michael Endl, MD, of Fichte, Endl & Elmer Eyecare, spoke with Ophthalmology 360 about his presentation at the 2026 ASCRS Annual Meeting, which covered the “next generation” of intraocular lenses...
Brandon Ayres, MD, of Wills Eye Hospital, spoke with Ophthalmology 360 about the phase 1/2 data assessing investigational treatment AURN001. The 1-year results showed positive changes in best-corrected vision. Brandon...
Kenneth Beckman, MD, of Columbus Eye Surgery Center, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about his study that found that at 30 months, treatment with Epioxa...
Brian Schwam, MD, of Johnson & Johnson Vision, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about the TECNIS PureSee intraocular lens (IOL). He presented a study that...